Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -94.89% | -67.96% | -52.51% | -47.56% | 967.22% |
| Depreciation & Amortization | 149.02% | 36.84% | 5,816.67% | 8,250.00% | -45.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -93.08% | -77.47% | -32.97% | -4.51% | 338.71% |
| Operating Income | 93.08% | 77.47% | 32.97% | 4.51% | -338.71% |
| Income Before Tax | 90.60% | 72.84% | 27.82% | 0.83% | -317.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 90.60% | 72.84% | 23.44% | 0.83% | -317.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.60% | 72.84% | 23.44% | 0.83% | -317.55% |
| EBIT | 93.08% | 77.47% | 32.97% | 4.51% | -338.71% |
| EBITDA | 93.21% | 77.85% | 35.34% | 5.78% | -340.20% |
| EPS Basic | 91.06% | 73.73% | 27.18% | 13.67% | -257.47% |
| Normalized Basic EPS | 91.00% | 73.82% | 31.47% | 13.75% | -256.79% |
| EPS Diluted | 91.06% | 73.73% | 27.18% | 13.67% | -257.47% |
| Normalized Diluted EPS | 91.00% | 73.82% | 31.47% | 13.75% | -256.79% |
| Average Basic Shares Outstanding | 4.76% | 3.77% | 5.29% | 14.93% | 16.94% |
| Average Diluted Shares Outstanding | 4.76% | 3.77% | 5.29% | 14.93% | 16.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |